BioNTech recruiting for BNT168 HIV vaccine Phase I/II trial
BioNTech's RNA-based BNT168 trial is recruiting adults with and without HIV to test safety, immune response, and viral control.
This week's update covers a single BioNTech trial record.
- BNT168 is an investigational RNA-based vaccine now in a Phase I/II trial recruiting adults living with and without HIV, with the study testing how safe it is, how well it triggers the body's immune response and how it affects the amount of virus in the body.1 The trial is recruiting, with an actual start date of August 4, 2026, and an estimated 126 participants.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.